Another phase I trial SG035-0002 was a dose-escalation study (0.4–1.4 mg/kg) of brentuximab vedotin given on days 1, 8, and 15 of 28-day cycles.37 Forty-four patients with relapsed or refractory CD30+ hematological malignancies were included, 38 of them with relapsed or refractory HL, 68% of all patients were previously treated with HDT. The gene discussed is TNFRSF8; the disease is Hodgkins lymphoma.